CTOs on the Move

Marker Therapeutics

www.markertherapeutics.com

 
We are a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Marker`s cell therapy technology is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor associated antigens (i.e. tumor targets) and kill tumor cells expressing those targets. Once infused into patients, this population of T cells attacks multiple tumor targets and acts to activate the patient`s immune system to produce broad spectrum anti-tumor activity. Because Marker does not genetically engineer its T cells, when compared to current engineered CAR-T and TCR-based approaches, ...
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Funding

Marker Therapeutics raised $56.5M on 03/12/2021

Similar Companies

NovaDel Pharma

NovaDel Pharma is a Flemington, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Qosina

Qosina is one of the leading medical device component suppliers of OEM components to medical and pharmaceutical industries. Explore our products today.

Oramed

Oramed Pharmaceuticals (Nasdaq/TASE: ORMP) is a platform technology pioneer in the field of oral delivery solutions for drugs currently delivered via injection. Established in 2006, with offices in the United States and Israel, Oramed has developed a novel Protein Oral Delivery (POD™) technology. Oramed is seeking to transform the treatment of diabetes through its proprietary lead candidate, ORMD-0801, which is being evaluated in two pivotal Phase 3 studies and has the potential to be the first commercial oral insulin capsule for the treatment of diabetes. In addition, Oramed is developing an oral GLP-1 (Glucagon-like peptide-1) analog capsule (ORMD-0901).

Draxis Pharma

Draxis Pharma is a Kirkland, QC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Clover Biopharmaceuticals

Founded in 2007, we are a global clinical-stage biotechnology company committed to developing novel vaccines and biologic therapeutic candidates for infectious diseases as well as cancer and autoimmune diseases. Our vision is to empower humanity with a healthier future through transformative science. Our mission is to leverage the Trimer-Tag™ technology platform and manufacturing capabilities for the discovery, development and commercialization of novel vaccines and biologic therapies.